Spots Global Cancer Trial Database for hodgkin lymphoma, adult
Every month we try and update this database with for hodgkin lymphoma, adult cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Immunogenicity of COVID-19 Vaccination in Autologous HSCT or CAR-T Cells Recipients | NCT05597761 | COVID-19 Non Hodgkin Lym... Hodgkin Lymphom... | 18 Years - | University of Cologne | ||
| PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin's Lymphoma | NCT05137886 | Hodgkin Lymphom... Relapse Refractory Hodg... | PD-1 inhibitor | 18 Years - 65 Years | Institute of Hematology & Blood Diseases Hospital, China | |
| Kinetic of Cytokines Decrease and Hodgkin Lymphoma Prognostic | NCT01833884 | Hodgkin's Disea... | Collection of b... | 18 Years - | Centre Henri Becquerel | |
| CAR T-cells Against CD30 (HSP-CAR30) for Relapsed/ Refractory Hodgkin and T-cell Lymphoma. | NCT04653649 | Hodgkin Lymphom... T Cell Lymphoma | HSP-CAR30 | 18 Years - 70 Years | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | |
| Immunogenicity of COVID-19 Vaccination in Autologous HSCT or CAR-T Cells Recipients | NCT05597761 | COVID-19 Non Hodgkin Lym... Hodgkin Lymphom... | 18 Years - | University of Cologne | ||
| Non-interventional, Long-term Follow-up of Subjects Who Completed ApoGraft-01 Study | NCT03260101 | Acute Myelogeno... Acute Lymphobla... Non Hodgkin Lym... Hodgkin Lymphom... | non intervation... | 18 Years - 70 Years | Cellect Biotechnology | |
| Kinetic of Cytokines Decrease and Hodgkin Lymphoma Prognostic | NCT01833884 | Hodgkin's Disea... | Collection of b... | 18 Years - | Centre Henri Becquerel | |
| Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin Lymphoma | NCT01578967 | Hodgkin Lymphom... | Brentuximab ved... ABVD | 18 Years - 60 Years | UNC Lineberger Comprehensive Cancer Center | |
| Elderly Hodgkin Lymphoma Patients Treated With Chemoradiotherapy | NCT03535948 | Hodgkin Lymphom... | 60 Years - | Central Hospital, Nancy, France | ||
| PD-1 Antibody SHR-1210 in Patients With Relapsed or Refractory Classic Hodgkin's Lymphoma | NCT03155425 | Hodgkin Lymphom... | SHR-1210 | 18 Years - | Jiangsu HengRui Medicine Co., Ltd. | |
| CAR T-cells Against CD30 (HSP-CAR30) for Relapsed/ Refractory Hodgkin and T-cell Lymphoma. | NCT04653649 | Hodgkin Lymphom... T Cell Lymphoma | HSP-CAR30 | 18 Years - 70 Years | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | |
| Molecular Imaging of Lymphoma Using Labeled Technetium-99m 1-Thio-D-Glucose | NCT04292626 | Hodgkin Lymphom... Non-Hodgkin Lym... | SPECT with 99mT... | 18 Years - 70 Years | Tomsk National Research Medical Center of the Russian Academy of Sciences | |
| Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma | NCT05798897 | Non-Hodgkin Lym... Non-Hodgkin Lym... Non-Hodgkin Lym... Non Hodgkin Lym... Hodgkin Lymphom... Hodgkin Lymphom... Hodgkin's Lymph... | MT-601 | 18 Years - 100 Years | Marker Therapeutics, Inc. | |
| Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin Lymphoma | NCT01578967 | Hodgkin Lymphom... | Brentuximab ved... ABVD | 18 Years - 60 Years | UNC Lineberger Comprehensive Cancer Center | |
| PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin's Lymphoma | NCT05137886 | Hodgkin Lymphom... Relapse Refractory Hodg... | PD-1 inhibitor | 18 Years - 65 Years | Institute of Hematology & Blood Diseases Hospital, China | |
| PD-1 Antibody SHR-1210 in Patients With Relapsed or Refractory Classic Hodgkin's Lymphoma | NCT03155425 | Hodgkin Lymphom... | SHR-1210 | 18 Years - | Jiangsu HengRui Medicine Co., Ltd. | |
| BREntuximab Vedotin in SEcond LIne Therapy BEfore Transplant | NCT04378647 | Hodgkin Lymphom... | Induction with ... Induction witho... Consolidation w... | 18 Years - 65 Years | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | |
| Non-interventional, Long-term Follow-up of Subjects Who Completed ApoGraft-01 Study | NCT03260101 | Acute Myelogeno... Acute Lymphobla... Non Hodgkin Lym... Hodgkin Lymphom... | non intervation... | 18 Years - 70 Years | Cellect Biotechnology | |
| Non-interventional, Long-term Follow-up of Subjects Who Completed ApoGraft-01 Study | NCT03260101 | Acute Myelogeno... Acute Lymphobla... Non Hodgkin Lym... Hodgkin Lymphom... | non intervation... | 18 Years - 70 Years | Cellect Biotechnology | |
| Compassionate Use Re-Infusion of ATLCAR.CD30 | NCT03914885 | Hodgkin Lymphom... | ATLCAR.CD30 Bendamustine Fludarabine | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Cardiopulmonary Function and Cerebral Blood Flow in Hodgkin Lymphoma Survivors | NCT06421987 | Hodgkin Lymphom... | Near Infrared S... | 18 Years - | St. Jude Children's Research Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
